Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Amgen hit with lawsuit over its proposed Opdivo biosimilar

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at lifesciencesipreview.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

Bristol-Myers Squibb (BMS) has filed a lawsuit against Amgen to protect its blockbuster cancer drug Opdivo, challenging Amgen's upcoming biosimilar launch.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Sep 2026 and 17 Sep 2026.

◆ ◆ The Wire takeaway

Your entry to the biosimilar market just got riskier as major drug patents are defended aggressively. This is a clear signal to secure your IP or prepare for legal battles if you target blockbuster biologics.

◆ Coverage

2 sources · first reported 16 Sep 2026 · latest 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarlawsuitcancer-drugpatent-disputebiotech